Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365532 · ClinicalTrials.gov registry record · Phase 1
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
A Phase 1 study of Long QT Syndrome, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02365532: Completed Phase 1 study of Long QT Syndrome, sponsored by Gilead Sciences.
NCT02365532 is a Phase 1 study of Long QT Syndrome that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants, below the 673-participant average among 7 other Long QT Syndrome trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365532, a Phase 1 study of Long QT Syndrome, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
Conditions Studied
Interventions
- DRUG GS-6615
- DRUG Placebo to match GS-6615
- DRUG Placebo to match dofetilide
- DRUG Dofetilide
Study Locations (1)
Wisconsin
- Spaulding Clinical Research, LLC - West Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02365532 record still lists
NCT02365532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 673-participant average among 7 other Long QT Syndrome trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Long QT Syndrome appearing as the primary indexed condition, and to 4 interventions - of which GS-6615 is the first listed.
NCT02365532 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02365532 about?
NCT02365532 is a clinical study titled "Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults". This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with dofetilide-induced QTc prolongation.
What is the current status of trial NCT02365532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-02. Estimated completion is 2015-05.
What conditions does trial NCT02365532 study?
This clinical trial studies the following conditions: Long QT Syndrome.
What interventions are being tested in trial NCT02365532?
The interventions under investigation include: GS-6615 (DRUG), Placebo to match GS-6615 (DRUG), Placebo to match dofetilide (DRUG), Dofetilide (DRUG).
Who is sponsoring clinical trial NCT02365532?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365532 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long QT Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Continuous Versus Intermittent cARdiac Electrical moNitorinG
RECRUITING · NA
-
Exercise in Genetic Cardiovascular Conditions
COMPLETED
-
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
COMPLETED · Phase 4
-
Long QT Syndrome and Sleep Apnea
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia